232 related articles for article (PubMed ID: 21175396)
1. The prevention of cervical cancer in Africa.
Fiander AN
Womens Health (Lond); 2011 Jan; 7(1):121-32. PubMed ID: 21175396
[TBL] [Abstract][Full Text] [Related]
2. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
3. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
4. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.
Mboumba Bouassa RS; Prazuck T; Lethu T; Jenabian MA; Meye JF; Bélec L
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):613-627. PubMed ID: 28440679
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.
Garcia FA; Saslow D
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):761-81, ix. PubMed ID: 18061868
[TBL] [Abstract][Full Text] [Related]
7. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
9. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer in sub-Saharan Africa: an emerging and preventable disease associated with oncogenic human papillomavirus.
Mboumba Bouassa RS; Prazuck T; Lethu T; Meye JF; Bélec L
Med Sante Trop; 2017 Feb; 27(1):16-22. PubMed ID: 28406406
[TBL] [Abstract][Full Text] [Related]
11. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
12. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
13. A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health.
Francis SA; Battle-Fisher M; Liverpool J; Hipple L; Mosavel M; Soogun S; Mofammere N
Vaccine; 2011 Nov; 29(47):8760-5. PubMed ID: 21855591
[TBL] [Abstract][Full Text] [Related]
14. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
16. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer.
Vetter KM; Geller SE
J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccines and prevention of cervical cancer.
Jansen KU; Shaw AR
Annu Rev Med; 2004; 55():319-31. PubMed ID: 14746524
[TBL] [Abstract][Full Text] [Related]
18. Screening for cervical cancer and human papillomavirus vaccination in Israel: recommendations.
Bornstein J; Fisher WA; Ginsberg GM; Shavit O; Schejter E; Diaz M; Bosch FX
Vaccine; 2013 Nov; 31 Suppl 8():I58-60. PubMed ID: 24229721
[No Abstract] [Full Text] [Related]
19. Primary and secondary prevention of cervical cancer.
Grce M
Expert Rev Mol Diagn; 2009 Nov; 9(8):851-7. PubMed ID: 19895230
[TBL] [Abstract][Full Text] [Related]
20. Introducing human papillomavirus vaccines into the health system in South Africa.
Botha MH; Dochez C
Vaccine; 2012 Sep; 30 Suppl 3():C28-34. PubMed ID: 22939017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]